A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1
258
about 4.4 years
18+
6 sites in CA, FL, MO +3
About this study
This trial is testing the safety of different doses of a new drug called BG-68501 in people with advanced cancers. The goal is to determine how safe and effective this treatment is, as well as how it works in the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BG-68501
- 2.Take BGB-43395
- 3.Take Fulvestrant
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
fulvestrant
injection
Primary: Part 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-68501, Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Part 2: Objective Response Rate (ORR)
Secondary: Part 1: Area under the concentration-time curve (AUC) for BG-68501 and BGB-43395, Part 1: Half-life (t1/2) for BG-68501 and BGB-43395, Part 1: Maximum observed plasma concentration (Cmax) for BG-68501 and BGB-43395, Part 1: ORR, Part 2: Number of participants with AEs and SAEs, Parts 1 and 2: Disease Control Rate (DCR), Parts 1 and 2: Duration of Response (DOR)
Oncology